Dechra Pharmaceuticals plc is a pharmaceutical company, focused on the veterinary market. Dechra Veterinary Products offers a range of specialist pharmaceutical products to veterinary practices in the United Kingdom, Europe and United States. The Company’s small animal portfolio includes therapies for key endocrine disorders, including Vetoryl for the treatment of canine hyperadrenocorticism (Cushing’s syndrome) and Felimazole for the treatment of feline hyperthyroidism. In April 2007, it acquired Leeds Veterinary Laboratories Limited. In September 2007, it announced that the United States Food and Drug Administration has granted Vetoryl Capsules a designation for a minor use in a major species (MUMS) to treat hyperadrenocorticism due to adrenocorticol tumors in dogs. In January 2008, the Company completed the acquisition of VetXX Holding A/S, which is a developer, producer and marketer of companion animal veterinary products.
